Chronic myeloid leukemia (CML) is a malignant disease that originates in the bone marrow
and is designated by the presence of the Philadelphia (Ph+) chromosome, a translocation …

MATERIALS AND METHODS: This prospective, randomized study included adult patients
(age> 18 years) with newly diagnosed CML-CP. Patients received either a single oral dose …

Abstract The Bcr-Abl inhibitor imatinib mesylate induces complete hematologic and
cytogenetic remissions in most newly diagnosed chronic myeloid leukemia (CML) patients …

Imatinib mesylate is a very effective treatment in patients with Philadelphia (Ph)‐positive
chronic myeloid leukaemia (CML). However, in patients with advanced phase CML, it is still …

The introduction of Imatinib (IM) has significantly altered the treatment for CML, although
only limited follow‐up results are available. As failure of Interferon‐α had been associated …

Chronic myeloid leukemia (CML) is a clonal stem-cell disorder in which the reciprocal
translocation t (9; 22) generates two novel fusion genes: BCR-ABL on the derivative 22q …

Imatinib (IM) at 400 mg daily is the first line therapy for newly diagnosed CML patients (pts);
however, less than 50% of major molecular responses (MMR) are obtained at 12 months. To …

BACKGROUND AND OBJECTIVES: Imatinib mesylate (STI571) is a selective inhibitor of the
bcr/abl tyrosine kinase with therapeutic potential in the blast crisis (BC) of chronic …

Imatinib is a tyrosine-kinase inhibitor that binds to ABL proteins and induces cytogenetic
remissions in patients with chronic myeloid leukemia (CML). In these patients measuring …

Imatinib (imatinib mesylate, Gleevec®[formerly known as STI571], Novartis Pharmaceuticals,
Basel, Switzerland) is a protein tyrosine kinase inhibitor that is approved by the US Food …